ascrinvacumab

Drug Overview

Ascrinvacumab is a highly specialized, investigational medication designed to treat various types of advanced cancers, including liver cancer (hepatocellular carcinoma) and urothelial (bladder) cancer. It represents an innovative approach to starving tumors of their nutrient supply.

• Generic Name: Ascrinvacumab
• US Brand Names: Currently in development under the investigational codes PF-03446962 and GT90001.
• Drug Class: Monoclonal Antibody / Angiogenesis Inhibitor. Highlight: This drug is classified as a Targeted Therapy, meaning it is built to seek out and interfere with specific proteins that help cancer survive, rather than attacking all fast-growing cells like traditional chemotherapy does.
• Route of Administration: Intravenous (IV) infusion (delivered directly into a vein).
• FDA Approval Status: Ascrinvacumab is currently an investigational drug. It is not yet fully FDA-approved for commercial sale. It is actively being studied in Phase 1 and Phase 2 clinical trials across the US and Europe to prove its safety and effectiveness.
  
  Explore the immune-modulating benefits of ascrinvacumab. Our top-rated medical hospital offers comprehensive care and expert clinical guidance.

What Is It and How Does It Work? (Mechanism of Action)

To survive and grow, tumors need a constant supply of oxygen and nutrients. They get this by tricking the body into building new blood vessels specifically for the tumora process called angiogenesis. Ascrinvacumab is designed to block this process.

Here is how ascrinvacumab works at the molecular level:

• Targeting the ALK-1 Receptor: The walls of our blood vessels are lined with endothelial cells. These cells have a special antenna on their surface called the ALK-1 (Activin receptor-like kinase 1) receptor. Tumors use this receptor to signal the body to grow new blood vessels.
• Blocking the Signal: Ascrinvacumab is a fully human antibody that specifically binds to the ALK-1 receptor. Once attached, it acts like a shield. It prevents the body’s natural growth signals (specifically proteins called BMP-9 and BMP-10) from connecting to the receptor.
• Shutting Down Growth Pathways: Because the growth signals are blocked, the inside of the cell cannot activate its normal building instructions (known as the SMAD signaling pathway). Without this pathway, the blood vessel cells cannot sprout, divide, or migrate toward the tumor.
• Starving the Cancer: By stopping the construction of new blood vessels, the tumor is cut off from its food and oxygen supply, which slows down or stops the cancer’s growth.

FDA-Approved Clinical Indications

Because ascrinvacumab is still in the clinical trial phase, it does not currently have official FDA approval for general prescription use.

• Oncological (Cancer) Uses (Investigational Only):
  • Hepatocellular Carcinoma (HCC) – Advanced liver cancer.
  • Urothelial Cancer – Advanced cancer of the bladder and urinary tract.
  • Advanced Solid Tumors – Various solid tumors that have not responded to other treatments.
• Non-oncological Uses:
  • There are currently no approved or investigational non-cancer uses for ascrinvacumab.

Dosage and Administration Protocols

As an investigational drug, the exact dosage is strictly controlled by clinical trial guidelines. Based on recent and ongoing trials, the following dosing structures have been utilized:

Clinical Efficacy and Research Results

Recent clinical trial data (spanning up to 2025) provides insight into how well ascrinvacumab works. Researchers are discovering that this drug works best when combined with other therapies.

• Liver Cancer (Hepatocellular Carcinoma): In Phase 1 and 2 trials studying ascrinvacumab on its own, the drug successfully stopped the disease from getting worse (achieved “stable disease”) in roughly 50% of treated patients. The median time before the disease started progressing again was about 3 months. Because single-agent results were modest, current clinical trials (such as those exploring GT90001) are combining ascrinvacumab with powerful immunotherapy drugs (like Nivolumab) to significantly boost survival rates in patients who did not respond to initial treatments.
• Urothelial Cancer: In a trial for patients with heavily pre-treated urothelial cancer, ascrinvacumab showed a median overall survival of approximately 8 months. However, the progression-free survival (the time patients lived without the cancer growing) was short (around 1.8 months). This confirmed that for bladder cancers, the drug needs to be paired with other targeted treatments rather than used alone.

Safety Profile and Side Effects

Like all powerful cancer treatments, ascrinvacumab can cause side effects. Because it affects blood vessels, its side effects are closely related to the circulatory system. Currently, there is no “Black Box Warning” as the drug is still investigational.

Common Side Effects (Occur in >10% of patients)

• Thrombocytopenia: A drop in blood platelets, which are responsible for helping blood clot.
• Asthenia and Fatigue: Feeling incredibly weak or tired.
• Chills and Mild Fevers: Often occurring shortly after the IV infusion.
• Abdominal Pain: Mild to moderate stomach discomfort.
• Telangiectasia: The appearance of small, widened blood vessels on the skin (like tiny spider veins).

Serious Adverse Events

• Severe Bleeding Risks: Because it targets blood vessels and lowers platelets, there is a higher risk of bleeding.
• Thromboembolic Events: A risk of dangerous blood clots, such as a pulmonary embolism (a clot in the lung).
• Elevated Pancreatic Enzymes: Increases in amylase and lipase, which can signal stress on the pancreas.

Management Strategies

• If platelets drop too low: Your doctor will delay your next infusion until your blood counts recover. In severe cases, a dose reduction may be applied.
• If you experience chills during infusion, The medical team may temporarily slow down the IV drip or give you medications like acetaminophen or antihistamines beforehand.
• If bleeding occurs: You must seek immediate emergency care. The drug will be paused while doctors manage the bleeding.

Connection to Stem Cell and Regenerative Medicine

Ascrinvacumab connects to the field of regenerative medicine through its impact on “endothelial progenitor cells, “a type of adult stem cell that circulates in the blood and helps build new blood vessels. Tumors often hijack these stem-like cells to create their own vascular networks. By blocking the ALK-1 pathway, ascrinvacumab disrupts the signals that tell these progenitor cells to differentiate and build tumor blood vessels. Researchers are studying how controlling these vascular stem cells might prevent cancer from spreading while preserving the body’s ability to heal normal, healthy tissue.

Patient Management and Practical Recommendations

Since this medication is given in a clinical trial setting, patient monitoring is highly rigorous.

Pre-Treatment Tests

• Comprehensive Blood Panels: Checking complete blood counts (especially platelets), liver enzymes, and kidney function.
• Pancreatic Tests: Blood tests to check amylase and lipase levels.
• Imaging: Baseline CT or MRI scans to map the exact size of the tumors before starting therapy.
• Heart and Clotting Checks: Ensuring you have no history of severe blood clots or active bleeding disorders.

Precautions During Treatment

• You will be monitored very closely for any signs of bleeding (such as nosebleeds, bleeding gums, or blood in the stool).
• Tell your medical team if you are taking any blood thinners (like aspirin or warfarin), as these can dangerously increase your bleeding risk when combined with ascrinvacumab.

“Do’s and Don’ts” List

• DO attend all scheduled blood test appointments. Your doctor relies on these to know if your body is tolerating the drug.
• DO report any sudden shortness of breath, chest pain, or leg swelling immediately, as these can be signs of a blood clot.
• DO use a soft-bristled toothbrush and an electric razor to minimize your risk of bleeding from small cuts.
• DON’T start any new medications, over-the-counter drugs, or herbal supplements without clearing them with your clinical trial coordinator first.
• DON’T ignore extreme fatigue or sudden, severe stomach pain. Contact your care team right away.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Ascrinvacumab is currently an investigational drug and is not approved by the FDA for commercial use. It should only be administered under the strict supervision of a qualified oncologist within an approved clinical trial setting. Always consult your healthcare provider regarding any medical conditions, treatments, or questions you may have about your health or participation in clinical trials.